Metropolitan Life Insurance Co NY Has $3.67 Million Stake in Haemonetics Co. (NYSE:HAE)

Share on StockTwits

Metropolitan Life Insurance Co NY trimmed its position in shares of Haemonetics Co. (NYSE:HAE) by 2.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 29,055 shares of the medical instruments supplier’s stock after selling 870 shares during the quarter. Metropolitan Life Insurance Co NY’s holdings in Haemonetics were worth $3,665,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in HAE. Alpha Windward LLC acquired a new stake in shares of Haemonetics during the 2nd quarter valued at about $29,000. Financial Gravity Wealth Inc. acquired a new stake in shares of Haemonetics during the 2nd quarter valued at about $40,000. Harvest Fund Management Co. Ltd acquired a new stake in shares of Haemonetics during the 2nd quarter valued at about $42,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in shares of Haemonetics during the 3rd quarter valued at about $58,000. Finally, Smithfield Trust Co. raised its stake in shares of Haemonetics by 18.8% in the 3rd quarter. Smithfield Trust Co. now owns 570 shares of the medical instruments supplier’s stock valued at $72,000 after acquiring an additional 90 shares in the last quarter. Institutional investors and hedge funds own 96.67% of the company’s stock.

A number of research analysts recently weighed in on HAE shares. Morgan Stanley raised their price objective on Haemonetics from $128.00 to $148.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Barrington Research reissued a “buy” rating and issued a $141.00 price objective on shares of Haemonetics in a research note on Monday, November 4th. ValuEngine downgraded Haemonetics from a “buy” rating to a “hold” rating in a research note on Monday, November 11th. JMP Securities raised their price objective on Haemonetics to $145.00 and gave the company an “outperform” rating in a research note on Wednesday, August 7th. Finally, Raymond James raised their price objective on Haemonetics from $110.00 to $150.00 and gave the company an “outperform” rating in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $144.80.

Shares of NYSE HAE opened at $120.60 on Monday. The company has a quick ratio of 1.35, a current ratio of 2.37 and a debt-to-equity ratio of 0.54. The business’s 50 day moving average is $122.79 and its two-hundred day moving average is $120.73. The company has a market cap of $6.11 billion, a P/E ratio of 50.46, a P/E/G ratio of 2.81 and a beta of 0.77. Haemonetics Co. has a 12 month low of $80.24 and a 12 month high of $140.36.

In other Haemonetics news, SVP Jacqueline Scanlan sold 1,531 shares of Haemonetics stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $127.44, for a total value of $195,110.64. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Ronald G. Gelbman sold 16,926 shares of Haemonetics stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $118.26, for a total value of $2,001,668.76. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 70,131 shares of company stock worth $8,512,917. Company insiders own 1.32% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Further Reading: What are trading strategies for the 52-week high/low?

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.